N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors
Abstract
:1. Introduction
2. Methods
2.1. Study Design
2.2. Study Population
2.3. Biomarker Assessment
2.4. Statistical Methods
3. Results
4. Discussion
4.1. Natriuretic Peptide
4.2. Soluble ST2
4.3. Galectin-3
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Patnaik, J.L.; Byers, T.; DiGuiseppi, C.; Dabelea, D.; Denberg, T.D. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study. Breast Cancer Res. 2011, 13, R64. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhao, R.; Shu, F.; Zhang, C.; Song, F.; Xu, Y.; Guo, Y.; Xue, K.; Lin, J.; Shu, X.; Hsi, D.H. Early Detection and Prediction of Anthracycline-Induced Right Ventricular Cardiotoxicity by 3-Dimensional Echocardiography. JACC Cardio Oncol. 2020, 2, 13–22. [Google Scholar] [CrossRef]
- Pinder, M.C.; Duan, Z.; Goodwin, J.S.; Hortobagyi, G.N.; Giordano, S.H. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J. Clin. Oncol. 2007, 25, 3808–3815. [Google Scholar] [CrossRef] [PubMed]
- Boerman, L.M.; Maass, S.W.M.C.; van der Meer, P.; Gietema, J.A.; Maduro, J.H.; Hummel, Y.M.; Berger, M.Y.; de Bock, G.H.; Berendsen, A.J. Long-term outcome of cardiac function in a population-based cohort of breast cancer survivors: A cross-sectional study. Eur. J. Cancer 2017, 81, 56–65. [Google Scholar] [CrossRef] [PubMed]
- Armenian, S.; Bhatia, S. Predicting and Preventing Anthracycline-Related Cardiotoxicity. Am. Soc. Clin. Oncol. Educ. Book 2018, 38, 3–12. [Google Scholar] [CrossRef]
- Felker, G.M.; Thompson, R.E.; Hare, J.M.; Hruban, R.H.; Clemetson, D.E.; Howard, D.L.; Baughman, K.L.; Kasper, E.K. Underlying Causes and Long-Term Survival in Patients with Initially Unexplained Cardiomyopathy. N. Engl. J. Med. 2000, 342, 1077–1084. [Google Scholar] [CrossRef]
- Brown, S.A.; Sandhu, N.; Herrmann, J. Systems biology approaches to adverse drug effects: The example of cardio-oncology. Nat. Rev. Clin. Oncol. 2015, 12, 718–731. [Google Scholar] [CrossRef]
- Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.; Coats, A.J.; Falk, V.; González-Juanatey, J.R.; Harjola, V.P.; Jankowska, E.A.; et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. J. Heart Fail. 2016, 18, 891–975. [Google Scholar] [CrossRef]
- Dixon, S.B.; Howell, C.R.; Lu, L.; Plana, J.C.; Joshi, V.M.; Luepker, R.V.; Durand, J.B.; Ky, B.; Lenihan, D.J.; Jefferies, J.L.; et al. Cardiac biomarkers and association with subsequent cardiomyopathy and mortality among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort. Cancer 2020, 127, 458–466. [Google Scholar] [CrossRef]
- York, M.K.; Gupta, D.K.; Reynolds, C.F.; Farber-Eger, E.; Wells, Q.S.; Bachmann, K.N.; Xu, M.; Harrell, F.E., Jr.; Wang, T.J. B-Type Natriuretic Peptide Levels and Mortality in Patients With and Without Heart Failure. J. Am. Coll. Cardiol. 2018, 71, 2079–2088. [Google Scholar] [CrossRef]
- Romano, S.; Fratini, S.; Ricevuto, E.; Procaccini, V.; Stifano, G.; Mancini, M.; Di Mauro, M.; Ficorella, C.; Penco, M. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br. J. Cancer 2011, 105, 1663–1668. [Google Scholar] [CrossRef] [Green Version]
- Blancas, I.; Martín-Pérez, F.J.; Garrido, J.M.; Rodríguez-Serrano, F. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients. Breast 2020, 54, 106–113. [Google Scholar] [CrossRef]
- Armenian, S.H.; Lacchetti, C.; Barac, A.; Carver, J.; Constine, L.S.; Denduluri, N.; Dent, S.; Douglas, P.S.; Durand, J.B.; Ewer, M.; et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2017, 35, 893–911. [Google Scholar] [CrossRef] [PubMed]
- Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E., Jr.; Drazner, M.H.; Fonarow, G.C.; Geraci, S.A.; Horwich, T.; Januzzi, J.L.; et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the american college of cardiology foundation/american heart association task force on practice guidelines. J. Am. Coll. Cardiol. 2013, 62, e147–e239. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Coglianese, E.E.; Larson, M.G.; Vasan, R.S.; Ho, J.E.; Ghorbani, A.; McCabe, E.L.; Cheng, S.; Fradley, M.G.; Kretschman, D.; Gao, W.; et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin. Chem. 2012, 58, 1673–1681. [Google Scholar] [CrossRef]
- Gaggin, H.K.; Szymonifka, J.; Bhardwaj, A.; Belcher, A.; De Berardinis, B.; Motiwala, S.; Wang, T.J.; Januzzi, J.L., Jr. Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15, and Highly-Sensitive Troponin T Measurements in Patients With Chronic Heart Failure. JACC Heart Fail. 2014, 2, 65–72. [Google Scholar] [CrossRef]
- Van Kimmenade, R.R.; Januzzi, J.L., Jr.; Ellinor, P.T.; Sharma, U.C.; Bakker, J.A.; Low, A.F.; Martinez, A.; Crijns, H.J.; MacRae, C.A.; Menheere, P.P.; et al. Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure. J. Am. Coll. Cardiol. 2006, 48, 1217–1224. [Google Scholar] [CrossRef] [Green Version]
- Ibrahim, N.E.; Januzzi, J.L. Beyond natriuretic peptides for diagnosis and management of heart failure. Clin. Chem. 2017. [Google Scholar] [CrossRef] [PubMed]
- Farhad, M.; Rolig, A.S.; Redmond, W.L. The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. Oncoimmunology 2018, 7, e1434467. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ebrahim, A.H.; Alalawi, Z.; Mirandola, L.; Rakhshanda, R.; Dahlbeck, S.; Nguyen, D.; Jenkins, M.; Grizzi, F.; Cobos, E.; Figueroa, J.A. Galectins in cancer: Carcinogenesis, diagnosis and therapy. Ann. Transl. Med. 2014, 2, 88. [Google Scholar] [CrossRef] [PubMed]
- Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E., Jr.; Colvin, M.M.; Drazner, M.H.; Filippatos, G.S.; Fonarow, G.C.; Givertz, M.M.; et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. J. Am. Coll. Cardiol. 2017, 136, e137–e161. [Google Scholar] [CrossRef]
- Mavinkurve-Groothuis, A.M.; Groot-Loonen, J.; Bellersen, L.; Pourier, M.S.; Feuth, T.; Bökkerink, J.P.; Hoogerbrugge, P.M.; Kapusta, L. Abnormal nt-pro-bnp levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines. Pediatr. Blood Cancer 2009, 52, 631–636. [Google Scholar] [CrossRef]
- Sherief, L.M.; Kamal, A.G.; Khalek, E.A.; Kamal, N.M.; Soliman, A.A.; Esh, A.M. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children. Hematology 2012, 17, 151–156. [Google Scholar] [CrossRef]
- Adams, M.J.; Lipshultz, S.E. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: Implications for screening and prevention. Pediatr. Blood Cancer 2005, 44, 600–606. [Google Scholar] [CrossRef] [PubMed]
- D’Errico, M.P.; Grimaldi, L.; Petruzzelli, M.F.; Gianicolo, E.A.; Tramacere, F.; Monetti, A.; Placella, R.; Pili, G.; Andreassi, M.G.; Sicari, R.; et al. N-terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012, 82, e239–e246. [Google Scholar] [CrossRef] [PubMed]
- Braunwald, E. Medical progress: Biomarkers in heart failure. N. Engl. J. Med. 2008, 358, 2148–2159. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Horacek, J.M.; Vasatova, M.; Tichy, M.; Pudil, R.; Jebavy, L.; Maly, J. The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia. Exp. Oncol. 2010, 32, 97–99. [Google Scholar] [PubMed]
- Ferraro, M.P.; Gimeno-Vazquez, E.; Subirana, I.; Gómez, M.; Díaz, J.; Sánchez-González, B.; García-Pallarols, F.; Martínez, L.; Ble, M.; Molina, L.; et al. Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification. Eur. J. Haematol. 2019, 102, 509–515. [Google Scholar] [CrossRef] [PubMed]
- Demissei, B.G.; Hubbard, R.A.; Zhang, L.; Smith, A.M.; Sheline, K.; McDonald, C.; Narayan, V.; Domchek, S.M.; DeMichele, A.; Shah, P.; et al. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. J. Am. Heart Assoc. 2020, 9, e014708. [Google Scholar] [CrossRef]
- Demissei, B.G.; Finkelman, B.S.; Hubbard, R.A.; Zhang, L.; Smith, A.M.; Sheline, K.; McDonald, C.; Narayan, H.K.; Narayan, V.; Waxman, A.J.; et al. Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy. Cancer 2019, 125, 2762–2771. [Google Scholar] [CrossRef] [PubMed]
- Zidan, A.; Sherief, L.M.; El-sheikh, A.; Saleh, S.H.; Shahbah, D.A.; Kamal, N.M.; Sherbiny, H.S.; Ahmad, H. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors. Dis. Markers 2015. [Google Scholar] [CrossRef] [Green Version]
- Armenian, S.H.; Mertens, L.; Slorach, C.; Venkataraman, K.; Mascarenhas, K.; Nathwani, N.; Wong, F.L.; Forman, S.J.; Bhatia, S. Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. Cancer 2018, 124, 850–857. [Google Scholar] [CrossRef]
- Armenian, S.H.; Gelehrter, S.K.; Vase, T.; Venkatramani, R.; Landier, W.; Wilson, K.D.; Herrera, C.; Reichman, L.; Menteer, J.D.; Mascarenhas, L.; et al. Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors. Clin. Cancer Res. 2014, 20, 6314–6323. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Clerico, A.; Cardinale, D.M.; Zaninotto, M.; Aspromonte, N.; Sandri, M.T.; Passino, C.; Migliardi, M.; Perrone, M.; Fortunato, A.; Padoan, A.; et al. High-sensitivity cardiac troponin i and T methods for the early detection of myocardial injury in patients on chemotherapy. Clin. Chem. Lab. Med. 2021, 59, 513–521. [Google Scholar] [CrossRef] [PubMed]
- Clerico, A.; Zaninotto, M.; Passino, C.; Aspromonte, N.; Piepoli, M.F.; Migliardi, M.; Perrone, M.; Fortunato, A.; Padoan, A.; Testa, A.; et al. Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers. Clin. Chem. Lab. Med. 2021, 59, 79–90. [Google Scholar] [CrossRef] [PubMed]
- Lyon, A.R.; Dent, S.; Stanway, S.; Earl, H.; Brezden-Masley, C.; Cohen-Solal, A.; Tocchetti, C.G.; Moslehi, J.J.; Groarke, J.D.; Bergler-Klein, J.; et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur. J. Heart Fail. 2020, 22, 1945–1960. [Google Scholar] [CrossRef]
- Dieplinger, B.; Egger, M.; Poelz, W.; Haltmayer, M.; Mueller, T. Long-term stability of soluble ST2 in frozen plasma samples. Clin. Biochem. 2010, 43, 1169–1170. [Google Scholar] [CrossRef] [PubMed]
- Mueller, T.; Gegenhuber, A.; Dieplinger, B.; Poelz, W.; Haltmayer, M. Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin. Chem. Lab. Med. 2004, 42, 942–944. [Google Scholar] [CrossRef] [PubMed]
- Schindler, E.I.; Szymanski, J.J.; Hock, K.G.; Geltman, E.M.; Scott, M.G. Short- and Long-term Biologic Variability of Galectin-3 and Other Cardiac Biomarkers in Patients with Stable Heart Failure and Healthy Adults. Clin. Chem. 2016, 62, 360–366. [Google Scholar] [CrossRef] [Green Version]
- Narayan, V.; Thompson, E.W.; Demissei, B.; Ho, J.E.; Januzzi, J.L.; Ky, B. Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2020, 75, 2726–2737. [Google Scholar] [CrossRef]
- Ho, J.E.; Liu, C.; Lyass, A.; Courchesne, P.; Pencina, M.J.; Vasan, R.S.; Larson, M.G.; Levy, D. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J. Am. Coll. Cardiol. 2012, 60, 1249–1256. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- | Did Not Receive Anthracycline (n = 580) | Received Anthracycline (n = 580) | Comparison 1 | p-Value 2 |
---|---|---|---|---|
Age at breast cancer diagnosis in years, mean (SD) | 52.4 (9.5) | 52.0 (9.7) | −0.3 (−0.4, −0.2) | <0.001 |
Time from breast cancer diagnosis to blood draw in years, mean (SD) | 2.7 (1.7) | 2.7 (1.7) | 0.01 (−0.01, 0.01) | 0.20 |
- | - | - | - | - |
Race, N (percent) | - | - | - | 0.71 |
White | 546 (94.1) | 549 (94.7) | 1.00 (ref) | - |
Other/unknown | 34 (5.9) | 31 (5.3) | 1.10 (0.67, 1.80) | - |
- | - | - | - | - |
Ethnicity, N (percent) | - | - | - | <0.001 |
Not Hispanic or Latino | 514 (88.6) | 549 (94.7) | 1.00 (ref) | - |
Other/unknown | 66 (11.4) | 31 (5.3) | 2.35 (1.48, 3.72) | - |
- | - | - | - | - |
Receipt of trastuzumab, N (percent) | - | - | - | <0.001 |
No | 534 (92.1) | 410 (70.7) | 1.00 (ref) | - |
Yes | 46 (7.9) | 170 (29.3) | 4.44 (3.10, 6.38) | - |
- | - | - | - | - |
- | Did Not Receive Anthracycline, Mean (SD) | Received Anthracycline, Mean (SD) | Mean Difference (95% CI) 1 | p-Value 2 | p-Value 3 |
---|---|---|---|---|---|
NT-proBNP (ng/L) | 97.0 (137.6) | 116.0 (153.3) | 19.0 (2.9, 35.1) | <0.001 | <0.001 |
sST2 (ng/L) | 25.1 (14.7) | 25.0 (14.5) | −0.1 (−1.7, 1.63) | 0.78 | 0.93 |
Galectin-3 (ng/L) | 16.1 (7.8) | 15.8 (7.5) | −0.3 (−1.2, 0.5) | 0.86 | 0.97 |
- | - | - | - | - | - |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Patel, S.R.; Herrmann, J.; Vierkant, R.A.; Olson, J.E.; Couch, F.J.; Hazim, A.; Sloan, J.A.; Loprinzi, C.L.; Ruddy, K.J. N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors. J. Clin. Med. 2021, 10, 3313. https://doi.org/10.3390/jcm10153313
Patel SR, Herrmann J, Vierkant RA, Olson JE, Couch FJ, Hazim A, Sloan JA, Loprinzi CL, Ruddy KJ. N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors. Journal of Clinical Medicine. 2021; 10(15):3313. https://doi.org/10.3390/jcm10153313
Chicago/Turabian StylePatel, Shruti Rajesh, Joerg Herrmann, Robert A. Vierkant, Janet E. Olson, Fergus J. Couch, Antonious Hazim, Jeff A. Sloan, Charles L. Loprinzi, and Kathryn J. Ruddy. 2021. "N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors" Journal of Clinical Medicine 10, no. 15: 3313. https://doi.org/10.3390/jcm10153313
APA StylePatel, S. R., Herrmann, J., Vierkant, R. A., Olson, J. E., Couch, F. J., Hazim, A., Sloan, J. A., Loprinzi, C. L., & Ruddy, K. J. (2021). N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors. Journal of Clinical Medicine, 10(15), 3313. https://doi.org/10.3390/jcm10153313